The Food and Drug Administration (FDA) has approved Tecentriq, in combination with carboplatin and etoposide for the first-line treatment of patients suffering from extensive-stage small cell lung cancer. Out of total lung cancers, about 10% to 15% consist of small cell lung cancer. When this type of cancer is found, it is generally at an